scholarly journals Efficacy and safety of iodine-125 brachytherapy combined with chemotherapy in the treatment of advanced NSCLC in the elderly

2018 ◽  
Vol Volume 11 ◽  
pp. 6617-6624 ◽  
Author(s):  
Chunrong Wu ◽  
Bo Li ◽  
Guiyin Sun ◽  
Chunfang Peng ◽  
Debing Xiang
Keyword(s):  
Advanced Nsclc ◽  
The Elderly ◽  
Efficacy And Safety ◽  
Iodine 125

scholarly journals Efficacy and Safety Aiming at the Combined-Modality Therapy of External Beam Radiotherapy (40Gy) and Iodine-125 Seed Implantation for Locally Advanced NSCLC in the Elderly

2020 ◽  
Author(s):  
LiJun Tian ◽  
HongZhi Liu ◽  
Qiang Zhang ◽  
Dian-Zhong Geng ◽  
Yu-Qing Huo ◽  
...  
Keyword(s):  
Chest Wall ◽  
Advanced Nsclc ◽  
Combined Modality Therapy ◽  
External Beam Radiotherapy ◽  
Locally Advanced ◽  
The Elderly ◽  
Seed Implantation ◽  
Combined Modality ◽  
Locally Advanced Nsclc ◽  
Iodine 125

Abstract Background Our retrospective study aimed to evaluate the efficacy and safety of the combined-modality therapy for tumor invading the chest wall of locally advanced non-small-cell lung cancer (NSCLC) in the elderly. Methods We retrospectively enrolled 21 elderly patients (aged ≥ 60 years) with locally advanced NSCLC diagnosed as tumor invading the chest wall. The prescription dose of the primary tumor adopting external beam radiotherapy (EBRT) was given 40 Gy which was supplemented with iodine-125 seed implantation, meanwhile the lymph nodes of mediastinum undergoing EBRT was given 60 Gy. Follow-up was conducted every 3 months postoperatively. The related analytic parameters were the change of tumor size, the objective response rate (ORR), the disease control rate (DCR), the degree of pain relief, the improvement of physical status and the toxicity. Results The combined-modality therapy could significantly inhibit the local growth of tumor (from 7.84 ± 1.20 to 4.69 ± 1.90 cm) (P < 0.0001), indicating a better validity with an ORR of 71.4% and DCR 90.5%, respectively at 1 year. The cancer-related pain was significantly relieved (P < 0.05) and the physical status were also significantly improved (P < 0.05). There was no procedure-associated death or grade > 2 irradiation-related adverse effect in our study. Conclusions The combined-modality therapy of EBRT with 40 Gy and permanent iodine-125 seed implantation is an efficacious and safe option and may be recommended as a treatment pattern for the elderly of locally advanced NSCLC with tumor invading the chest wall.

Long-term efficacy and safety of imiquimod 5% and fluorouracil 1% creams in medical monotherapy of complex eyelid basal cell carcinomas

2021 ◽  
pp. 112067212110356
Author(s):  
Manpreet Singh ◽  
Aditi Mehta Grewal ◽  
Himanshi Singh ◽  
Manjula Sharma ◽  
Manpreet Kaur ◽  
...  
Keyword(s):  
Basal Cell ◽  
Side Effect ◽  
The Elderly ◽  
Fixed Dose ◽  
Side Effect Profile ◽  
Efficacy And Safety ◽  
Term Efficacy ◽  
Basal Cell Carcinomas ◽  
Double Blinded

Purpose: To study the long-term efficacy and safety of local application of imiquimod 5% and fluorouracil 1% creams in complex eyelid basal cell carcinomas (BCCs). Methods: A retrospective, non-comparative study in biopsy-proven, complex (involving canthi or >50% of eyelid length) eyelid BCC patients who were medically unfit for surgical procedures. All patients were medically treated with either of the creams using fixed-dose regimens for a minimum of 3 months. All received oral vitamin C 500 mg QID for 3 months as an adjunct for collagen healing. A minimum of “post-treatment” follow-up of 12 months was observed. Results: Of total 30 patients, imiquimod 5% and fluorouracil 1% were used in 16 and 14 patients, respectively. The mean age of our patients was 70.5 years. The co-morbidities included – severe coronary artery disease using blood-thinners ( n = 19), poorly controlled diabetes ( n = 12), poorly controlled hypertension ( n = 6), on nebulization ( n = 3), and tuberculosis with pulmonary fibrosis ( n = 2). Complete clinical tumor resolution was noted in 10 and 8 patients over 12 and 16.5 weeks, respectively, in imiquimod and fluorouracil groups. Periocular skin erythema, chemical conjunctivitis, and skin depigmentation were seen in all the patients of imiquimod group. On the other hand, the local side-effect profile in fluorouracil patients was limited. Conclusion: The medical treatment of complex eyelid BCC is a useful alternative to surgery in the elderly with significant co-morbidities. It provides a promising long-term relief with a tolerable side-effect profile. A prospective, randomized, double-blinded trial would provide stronger evidence for the efficacy of these drugs.

scholarly journals The Influence of KDR Genetic Variation on the Efficacy and Safety of Patients With Advanced NSCLC Receiving First-Line Bevacizumab Plus Chemotherapy Regimen

2021 ◽  
Vol 20 ◽  
pp. 153303382110194
Author(s):  
Nan Geng ◽  
Jingwei Su ◽  
Zhikun Liu ◽  
Cuimin Ding ◽  
Shaonan Xie ◽  
...  
Keyword(s):  
Genetic Variation ◽  
Regression Analysis ◽  
Mrna Expression ◽  
Advanced Nsclc ◽  
Cox Regression ◽  
Chemotherapy Regimen ◽  
Efficacy And Safety ◽  
First Line ◽  
Cox Regression Analysis ◽  
Tissue Specimens

Objective: Angiogenesis plays an important role in the growth and metastasis of non-small cell lung cancer (NSCLC). Bevacizumab is a humanized monoclonal antibody that mainly acts on vascular endothelial growth factor A (VEGFA). Kinase insert domain receptor (KDR) is the most important target of VEGFA. The aim of present study was to investigate the influence of KDR genetic variation on the efficacy and safety of patients with advanced NSCLC receiving first-line bevacizumab plus chemotherapy regimen. Methods: A total of 169 patients with advanced NSCLC who received bevacizumab combined with chemotherapy were recruited in this study. Clinical outcome of the regimens was evaluated in the hospital. Peripheral blood and biopsy tissue specimens of patients were collected for the genotyping of KDR genetic variation and KDR mRNA expression, respectively. The association between KDR genotype status and other variables were analyzed. Univariate analysis of genotype status and prognosis was implemented using the Kaplan-Meier survival analysis method. Multivariate Cox regression analysis was performed to adjust the confounding factors. Results: Of the polymorphisms analyzed, only V297 L was of clinical significance. The prevalence of V297 L among the study population were as follows: CC genotype 123 cases (72.8%), CT genotype 41 cases (24.3%), TT genotype 5 cases (2.9%). The minimum allele frequency is 0.15. The distribution frequencies of the 3 genotypes corresponded with Hardy-Weinberg equilibrium ( P = 0.489). Patients with TT and CT genotypes were merged in the subsequent comparison of clinical outcomes. The analysis of efficacy exhibited that the objective response rates (ORR) of patients with CC genotype and CT/TT genotypes were 52.8% and 47.8% ( P = 0.561), respectively. Prognosis indicated that the median progression free survival (PFS) of patients with CC genotype and CT/TT genotype were 8.9 and 5.5 months, respectively ( P = 0.006). The median OS of the 2 genotypes were 20.0 and 14.9 months, respectively ( P = 0.021). Adjusted in multivariate Cox regression analysis of PFS, CT/TT genotypes were an independent factor for PFS [hazard ratio (HR) = 1.59, P = 0.011). Safety profile according to genotype status of V297 L failed to find significant difference. Interestingly, the expression of KDR mRNA of patients with CT/TT genotype was significantly higher than that of patients with CC genotype in the 58 cancer tissue specimens ( P < 0.001). Conclusion: The clinical comes of patients with advanced NSCLC receiving first-line bevacizumab plus chemotherapy regimens might be impacted by polymorphism V297 L through mediating the mRNA expression of KDR.

Sign in / Sign up

Export Citation Format

Share Document